Drugs / GW-328267
GW-328267
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01640990 | Nov → Dec 2011 | acute lung injury | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GW-328267 | ChEMBL registry synonym — accepted as the source's own label CHEMBL186113 ↗ |
| Known as | GW328267X | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01640990 ↗ |
| Known as | J2.047.755E | ChEMBL registry synonym — accepted as the source's own label CHEMBL186113 ↗ |
| Modality | Small molecule | — CHEMBL186113 ↗ |
| Route | Intravenous | “slow IV infusion over 6 hours consisting of saline for 30 minutes (run in period), 8 mcg/h GW328267X for 1.5 hours (total dose of 12mcg) and 10 mcg/h GW328267X for 4 hours...” NCT01640990 ↗ |